3,5-dimethylimidazolidine-2,4-dione

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (4-bromo-2-fluorophenyl)[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (167 mg) described in Preparation Example 121 and 3,5-dimethylimidazolidine-2,4-dione (51 mg) described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536, the title compound (51 mg) was obtained. described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (4-bromophenyl) [4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (160 mg) described in Preparation Example 185 and 3,5-dimethylimidazolidine-2,4-dione (51 mg) described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536, the title compound (20 mg) was obtained. described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (6-bromopyridin-3-yl) [4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (100 mg) described in Preparation Example 144 and 3,5-dimethylimidazolidine-2,4-dione (64 mg) described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536, the title compound (13 mg) was obtained. described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (6-bromopyridin-3-yl) [4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (100 mg) described in Preparation Example 144 and 3,5-dimethylimidazolidine-2,4-dione (64 mg) described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536, the title compound (13 mg) was obtained. described in Preparation Example 217 and by the reaction and treatment in the same manner as in Example 536

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using methyl 6-bromo-2-methylnicotinate (96 mg) and 3,5-dimethylimidazolidine-2,4-dione (107 mg) described in Preparation Example 217 and by the reaction and treatment in the same manner as in Preparation Example 48, the title compound (19 mg) was obtained. described in Preparation Example 217 and by the reaction and treatment in the same manner as in Preparation Example 48

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using 5-methylimidazolidine-2,4-dione (1.00 g) and methyl iodide (0.57 mL) and by the reaction and treatment in the same manner as in Preparation Example 214, the title compound (1.66 g, containing DMF) was obtained. by the reaction and treatment in the same manner as in Preparation Example 214

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using 5-methylimidazolidine-2,4-dione (1.00 g) and methyl iodide (0.57 mL) and by the reaction and treatment in the same manner as in Preparation Example 214, the title compound (1.66 g, containing DMF) was obtained. by the reaction and treatment in the same manner as in Preparation Example 214